Gil Blum
Stock Analyst at Needham
(3.59)
# 831
Out of 5,072 analysts
414
Total ratings
38.78%
Success rate
8.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Maintains: Buy | $8 → $7 | $3.07 | +128.01% | 6 | Nov 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $81 → $80 | $53.57 | +49.34% | 26 | Nov 10, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $26 | $17.00 | +52.94% | 27 | Nov 4, 2025 | |
| TCRX TScan Therapeutics | Maintains: Buy | $9 → $6 | $0.98 | +513.18% | 8 | Nov 4, 2025 | |
| AUTL Autolus Therapeutics | Reiterates: Buy | $10 | $1.39 | +619.42% | 31 | Nov 3, 2025 | |
| CELC Celcuity | Reiterates: Buy | $70 | $99.08 | -29.35% | 21 | Oct 20, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Buy | $10 | $4.59 | +117.86% | 31 | Oct 17, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Buy | $18 | $3.35 | +438.12% | 7 | Oct 17, 2025 | |
| RXRX Recursion Pharmaceuticals | Reiterates: Buy | $8 | $4.37 | +83.07% | 25 | Sep 11, 2025 | |
| NKTX Nkarta | Reiterates: Buy | $10 | $1.81 | +452.49% | 18 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | n/a | $19.35 | - | 38 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | n/a | $3.10 | - | 22 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $1.79 | +179.33% | 19 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $40 | $7.32 | +446.45% | 15 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $71 | $39.87 | +78.08% | 14 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.01 | - | 16 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $105 | $73.00 | +43.84% | 23 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $13.95 | +244.09% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.16 | +331.03% | 23 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Suspends: Buy | $15 | $5.31 | +182.49% | 19 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.06 | - | 9 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $14 | $9.87 | +41.84% | 7 | Sep 18, 2025 |
Absci
Nov 13, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.07
Upside: +128.01%
CRISPR Therapeutics AG
Nov 10, 2025
Maintains: Buy
Price Target: $81 → $80
Current: $53.57
Upside: +49.34%
Nurix Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $26
Current: $17.00
Upside: +52.94%
TScan Therapeutics
Nov 4, 2025
Maintains: Buy
Price Target: $9 → $6
Current: $0.98
Upside: +513.18%
Autolus Therapeutics
Nov 3, 2025
Reiterates: Buy
Price Target: $10
Current: $1.39
Upside: +619.42%
Celcuity
Oct 20, 2025
Reiterates: Buy
Price Target: $70
Current: $99.08
Upside: -29.35%
Taysha Gene Therapies
Oct 17, 2025
Reiterates: Buy
Price Target: $10
Current: $4.59
Upside: +117.86%
Artiva Biotherapeutics
Oct 17, 2025
Reiterates: Buy
Price Target: $18
Current: $3.35
Upside: +438.12%
Recursion Pharmaceuticals
Sep 11, 2025
Reiterates: Buy
Price Target: $8
Current: $4.37
Upside: +83.07%
Nkarta
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $1.81
Upside: +452.49%
Jul 29, 2025
Reiterates: Underperform
Price Target: n/a
Current: $19.35
Upside: -
Jul 24, 2025
Maintains: Hold
Price Target: n/a
Current: $3.10
Upside: -
Jul 10, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $1.79
Upside: +179.33%
May 8, 2025
Maintains: Buy
Price Target: $41 → $40
Current: $7.32
Upside: +446.45%
Apr 10, 2025
Reiterates: Buy
Price Target: $71
Current: $39.87
Upside: +78.08%
Mar 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $2.01
Upside: -
Dec 10, 2024
Reiterates: Buy
Price Target: $105
Current: $73.00
Upside: +43.84%
Aug 2, 2024
Reiterates: Buy
Price Target: $48
Current: $13.95
Upside: +244.09%
Apr 11, 2024
Reiterates: Buy
Price Target: $5
Current: $1.16
Upside: +331.03%
Nov 7, 2025
Suspends: Buy
Price Target: $15
Current: $5.31
Upside: +182.49%
Oct 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.06
Upside: -
Sep 18, 2025
Upgrades: Buy
Price Target: $14
Current: $9.87
Upside: +41.84%